GMED recently reported inline earnings but has now come to our attention on the possibility of a substantial breakout, it has also come to light that multiple Investment and Capital management firms have made significant acquisitions of the stock. This has brought it to the attention of many and has helped and will continue to propel the stock higher in our opinion.
AVERAGE ANALYSTS PRICE TARGET $53
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 35
SHORT INTEREST 3.4%
COMPANY PROFILE
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul in March 2003 and is headquartered in Audubon, PA.
AVERAGE ANALYSTS PRICE TARGET $53
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
P/E RATIO 35
SHORT INTEREST 3.4%
COMPANY PROFILE
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul in March 2003 and is headquartered in Audubon, PA.